AusperBio Secures $63 Million Series B2 Financing to Propel AHB‑137 Development
AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively “AusperBio”) announced that it has closed...
AusperBio
AusperBio Gains NMPA Approval for Phase III Trials of AHB-137 in Chronic Hepatitis B
Sino-US liver therapy developer AusperBio announced that the National Medical Products Administration (NMPA) has approved...
AusperBio Secures $50M in Oversubscribed Series B+ Round to Advance Hepatitis B Therapy
Sino-US liver therapy developer AusperBio announced the successful closing of an oversubscribed Series B+ financing...
AusperBio Secures $73 Million in Series B Financing to Advance Hepatitis B Therapy
Sino-US liver therapy developer AusperBio has announced the completion of a USD 73 million Series...
AusperBio Secures $37 Million in Series A Funding to Advance Hepatitis B Therapy AHB-137
AusperBio, a sino-American biotechnology company specializing in liver therapy development, has reportedly secured USD 37...
AusperBio’s AHB-137 Antiviral Candidate on Path to Breakthrough Designation for Chronic Hepatitis B in China
AusperBio, a sino-American developer specializing in liver therapies, has announced that its drug candidate AHB-137...
AusperBio and Asymchem Form Strategic Partnership for Drug Development
China-based firms AusperBio and Asymchem (SHE: 002821, HKG: 6821) have entered into a strategic partnership...
AusperBio and Asymchem Form Strategic Partnership for New Drug R&D and Services
China-based firms AusperBio and Asymchem (SHE: 002821, HKG: 6821) have entered into a strategic partnership...
AusperBio Initiates Phase I Trial for AHB-137 in New Zealand
Sino-US liver therapy developer AusperBio has announced the initiation of the first cohort dosing in...
Ausper Biopharma’s COVID-19 Nasal Spray Antibody Gets NMPA Approval
Ausper Biopharma Inc., a Hangzhou-based developer of hepatitis B virus (HBV) drugs, announced that its...
Ausper Biopharma Raises USD 16M for HBV Drug and Vaccine Development
Ausper Biopharma, Inc, a developer of drugs and vaccines for chronic hepatitis B virus (HBV)...